CoChat

Resvega, a Nutraceutical Preparation, Affects NFκB Pathway and Prolongs the Anti-VEGF Effect of Bevacizumab in Undifferentiated ARPE-19 Retina Cells

Open access
Sghaier, Randa, Perus, Maude, Cornebise, Clarisse, Courtaut, Flavie, Scagliarini, Alessandra, Olmiere, Céline, Aires, Virginie, Hermetet, François, Delmas, Dominique · 2022 · International Journal of Molecular Sciences

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Abstract

Age-related macular degeneration (AMD) is an irreversible chronic degenerative pathology that affects the retina. Despite therapeutic advances thanks to the use of anti-vascular endothelial growth factor (VEGF) agents, resistance mechanisms have been found to accentuate the visual deficit. In the present study, we explored whether a nutraceutical formulation composed of omega-3 fatty acids and resveratrol, called Resvega®, was able to disrupt VEGF-A secretion in human ARPE-19 retina cells. We found that Resvega® inhibits VEGF-A secretion through decreases in both the PI3K-AKT-mTOR and NFκB signaling pathways. In NFκB signaling pathways, Resvega® inhibits the phosphorylation of the inhibitor of NFκB, IκB, which can bind NFκB dimers and sequester them in the cytoplasm. Thus, the NFκB subunits cannot migrate to the nucleus where they normally bind and stimulate the transcription of target genes such as VEGF-A. The IκB kinase complex (IKK) is also affected by Resvega® since the nutraceutical formulation decreases both IKKα and IKKβ subunits and the IKKγ subunit which is required for the stimulation of IKK. Very interestingly, we highlight that Resvega® could prolong the anti-angiogenic effect of Avastin®, which is an anti-VEGF agent typically used in clinical practice. Our results suggest that Resvega® may have potential interest as nutritional supplementation against AMD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms231911704

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 RGA formulation disrupts VEGF-A secretion over time in human ARPE-19 retina cells. (A) ARPE-19 retina cells were treated for 24, 48 and 72 h without serum with vehicle as control (Co) or with RGA (12 µM). VEGF-A secretion was measured in cell medium by ELISA assay. The data are mean ± S.D. of four independent experiments with n = 10. p values were determined by one-way ANOVA followed by Tukey’s multiple comparison test of treatments vs. control. * p < 0.05, and *** p < 0.001. (B) ARPE-19 cells were treated with 12 µM of RGA at 37 °C for 24, 48 and 72 h. The percentage of cell viability was determined by crystal violet assay. Results are expressed as a percentage of control (mean ± SD of three independent experiments with n = 10). (C) Immunoblot analysis of ZO-1 in RGA treated ARPE-19 cells with increasing concentration (0.6, 3, 6, 12 µM) or with vehicle (Co) for 24 h. HSC-70 was used as a loading control. (D) Densitometry quantification of western blotting. Data are expressed as the mean fold induction compared to control (Co).
Figure 1 RGA formulation disrupts VEGF-A secretion over time in human ARPE-19 retina cells. (A) ARPE-19 retina cells were treated for 24, 48 and 72 h without serum with vehicle as control (Co) or with RGA (12 µM). VEGF-A secretion was measured in cell medium by ELISA assay. The data are mean ± S.D. of four independent experiments with n = 10. p values were determined by one-way ANOVA followed by Tukey’s multiple comparison test of treatments vs. control. * p < 0.05, and *** p < 0.001. (B) ARPE-19 cells were treated with 12 µM of RGA at 37 °C for 24, 48 and 72 h. The percentage of cell viability was determined by crystal violet assay. Results are expressed as a percentage of control (mean ± SD of three independent experiments with n = 10). (C) Immunoblot analysis of ZO-1 in RGA treated ARPE-19 cells with increasing concentration (0.6, 3, 6, 12 µM) or with vehicle (Co) for 24 h. HSC-70 was used as a loading control. (D) Densitometry quantification of western blotting. Data are expressed as the mean fold induction compared to control (Co).CC BY · PubMed Central
Figure 2 RSV/ω-3 fatty acids combination disrupts PI3K-AKT-mTOR signaling pathway. (A) Immunoblot analysis of c-RAF, phospho-c-RAF (p-RAF), PI3K, AKT, phospho-AKT (p-AKT), mTOR, phospho-mTOR (p-mTOR) in RGA-treated ARPE-19 cells with increasing concentration (0.6, 3, 6, 12 µM) or with vehicle (Co) for 24 h. β-ACTIN was used as a loading control. (B) Densitometry quantification of western blotting. Data are expressed as the mean fold induction ± SEM of three independent experiments. p-values were determined by a one-way ANOVA followed by Tukey’s multiple comparison test of treatments vs. control. * p < 0.05, ** p < 0.01, *** p < 0.001, and # p < 0.0001.
Figure 2 RSV/ω-3 fatty acids combination disrupts PI3K-AKT-mTOR signaling pathway. (A) Immunoblot analysis of c-RAF, phospho-c-RAF (p-RAF), PI3K, AKT, phospho-AKT (p-AKT), mTOR, phospho-mTOR (p-mTOR) in RGA-treated ARPE-19 cells with increasing concentration (0.6, 3, 6, 12 µM) or with vehicle (Co) for 24 h. β-ACTIN was used as a loading control. (B) Densitometry quantification of western blotting. Data are expressed as the mean fold induction ± SEM of three independent experiments. p-values were determined by a one-way ANOVA followed by Tukey’s multiple comparison test of treatments vs. control. * p < 0.05, ** p < 0.01, *** p < 0.001, and # p < 0.0001.CC BY · PubMed Central
Figure 3 RSV/ω-3 fatty acids combination decreases NFκB complex protein expression. (A) Immunoblot analysis of P105, P50, phospho-P65, (p-P65), P65, phospho-IκBα (p-IκBα), IκBα in RGA-treated ARPE-19 cells with increasing concentration (0.6, 3, 6, 12 µM) or with vehicle (Co) for 24 h. HSC-70 was used as a loading control. (B) Densitometry quantification of western blotting. Data are expressed as the mean fold induction ± SEM of three independent experiments. p values were determined by a one-way ANOVA followed by Tukey’s multiple comparison test of treatments vs. control. * p < 0.05, ** p < 0.01 and *** p < 0.001.
Figure 3 RSV/ω-3 fatty acids combination decreases NFκB complex protein expression. (A) Immunoblot analysis of P105, P50, phospho-P65, (p-P65), P65, phospho-IκBα (p-IκBα), IκBα in RGA-treated ARPE-19 cells with increasing concentration (0.6, 3, 6, 12 µM) or with vehicle (Co) for 24 h. HSC-70 was used as a loading control. (B) Densitometry quantification of western blotting. Data are expressed as the mean fold induction ± SEM of three independent experiments. p values were determined by a one-way ANOVA followed by Tukey’s multiple comparison test of treatments vs. control. * p < 0.05, ** p < 0.01 and *** p < 0.001.CC BY · PubMed Central
Figure 4 RGA disturbs the translocation of the P65 and P50 dimer subunits of NFkB into the nucleus of ARPE-19 cells. (A). Representative blot of P105, P50, P65 protein expression in concentration range of RGA (0.6, 3, 6, 12 µM)-treated or not (Co) ARPE-19 cells for 24 h. Nuclear fractions and cytosolic fractions are shown from three independent experiments. (B) Densitometry quantification of western blotting from the representative nuclear and cytosolic immunoblotting. Data are expressed as the mean fold induction.
Figure 4 RGA disturbs the translocation of the P65 and P50 dimer subunits of NFkB into the nucleus of ARPE-19 cells. (A). Representative blot of P105, P50, P65 protein expression in concentration range of RGA (0.6, 3, 6, 12 µM)-treated or not (Co) ARPE-19 cells for 24 h. Nuclear fractions and cytosolic fractions are shown from three independent experiments. (B) Densitometry quantification of western blotting from the representative nuclear and cytosolic immunoblotting. Data are expressed as the mean fold induction.CC BY · PubMed Central
Figure 5 The RSV/ω-3 fatty acids combination decreases subunits of IκB complex protein expression. (A) Immunoblot analysis of IKKα, IKKβ, phospho-IKKαβ (p-IKKαβ), IKKγ in RGA-treated ARPE-19 cells with increasing concentrations (0.6, 3, 6, 12 µM) or with vehicle (Co) for 24 h. HSC-70 was used as a loading control. (B) Densitometry quantification of western blotting. Data are expressed as the mean fold induction ± SEM of three independent experiments. p values were determined by a one-way ANOVA followed by Tukey’s multiple comparison test of treatments vs. control. * p < 0.05 and ** p < 0.01.
Figure 5 The RSV/ω-3 fatty acids combination decreases subunits of IκB complex protein expression. (A) Immunoblot analysis of IKKα, IKKβ, phospho-IKKαβ (p-IKKαβ), IKKγ in RGA-treated ARPE-19 cells with increasing concentrations (0.6, 3, 6, 12 µM) or with vehicle (Co) for 24 h. HSC-70 was used as a loading control. (B) Densitometry quantification of western blotting. Data are expressed as the mean fold induction ± SEM of three independent experiments. p values were determined by a one-way ANOVA followed by Tukey’s multiple comparison test of treatments vs. control. * p < 0.05 and ** p < 0.01.CC BY · PubMed Central
Figure 6 RSV/ω-3 fatty acids prolong the VEGF-A inhibition induced by Avastin®. (A) Experimental workflow. After 24 h of culture, ARPE-19 retina cells were treated with 12 µM of RGA or with vehicle during 72 h, and then exposed to Avastin® at 100 ng/mL during 24 or 48 h. At each time point, the level of VEGF-A secreted was measured by ELISA assay as well as the percentage of viable cells by crystal violet assay. (B) Histograms of the concentration of secreted VEGF-A (pg/mL) normalized to cell viability after 24 or 48 h or treatment with Avastin® (100 ng/mL) in ARPE-19 retina cells, and pretreated or not with RGA (12 µM). Data are expressed as the mean fold induction ± SEM of the three independent experiments. p values were determined by a one-way ANOVA followed by Tukey’s multiple comparison test to 2 groups (control group vs. treatment group and treatment group vs. treatment group). # p < 0.0001.
Figure 6 RSV/ω-3 fatty acids prolong the VEGF-A inhibition induced by Avastin®. (A) Experimental workflow. After 24 h of culture, ARPE-19 retina cells were treated with 12 µM of RGA or with vehicle during 72 h, and then exposed to Avastin® at 100 ng/mL during 24 or 48 h. At each time point, the level of VEGF-A secreted was measured by ELISA assay as well as the percentage of viable cells by crystal violet assay. (B) Histograms of the concentration of secreted VEGF-A (pg/mL) normalized to cell viability after 24 or 48 h or treatment with Avastin® (100 ng/mL) in ARPE-19 retina cells, and pretreated or not with RGA (12 µM). Data are expressed as the mean fold induction ± SEM of the three independent experiments. p values were determined by a one-way ANOVA followed by Tukey’s multiple comparison test to 2 groups (control group vs. treatment group and treatment group vs. treatment group). # p < 0.0001.CC BY · PubMed Central
Figure 7 Schematic illustration of the novel proposed mechanisms of the anti-angiogenic impact of Resvega® (RGA), which is able to target several angiogenesis molecular pathways in human ARPE-19 retina cell model. RGA counteracts angiogenic VEGF-A production through an alteration of the AKT/PI3K and NFκB pathways. In detail, RGA reduces the regulator complex IKK controlling the downstream NFκB subunits P65 and P50 belonging and their nuclear/cytosolic localization. This new RGA-targeted pathway complements data on the impact of RGA, which we have previously demonstrated to be involved in preventing activation of the MAPK signaling pathway in ARP19 cells [22]. The disruption of these two important angiogenesis signaling pathways likely leads to a sensitization of retina cells to the anti-VEGF treatment, resulting in an increased ability of Avastin® to decrease VEGF-A secretion over time.
Figure 7 Schematic illustration of the novel proposed mechanisms of the anti-angiogenic impact of Resvega® (RGA), which is able to target several angiogenesis molecular pathways in human ARPE-19 retina cell model. RGA counteracts angiogenic VEGF-A production through an alteration of the AKT/PI3K and NFκB pathways. In detail, RGA reduces the regulator complex IKK controlling the downstream NFκB subunits P65 and P50 belonging and their nuclear/cytosolic localization. This new RGA-targeted pathway complements data on the impact of RGA, which we have previously demonstrated to be involved in preventing activation of the MAPK signaling pathway in ARP19 cells [22]. The disruption of these two important angiogenesis signaling pathways likely leads to a sensitization of retina cells to the anti-VEGF treatment, resulting in an increased ability of Avastin® to decrease VEGF-A secretion over time.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 45 references

Cited by

See all 17

Metadata

Authors
Sghaier, R., Perus, M., Cornebise, C., Courtaut, F., Scagliarini, A., Olmiere, C., Aires, V., Hermetet, F., & Delmas, D.
Affiliations
  • Inserm (FR)
  • Laboratoires Théa<sup>®</sup>, 12 Rue Louis-Blériot, 63000 Clermont-Ferrand, France
Corresponding author
Delmas, Dominique
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2022-10-03
Volume
23
Issue
19
Pages
11704
ISSN
1422-0067 (ISSN-L)
OpenAlex
W4303699621
Cited by
11
References
45
Citations by year
2026: 2 · 2025: 3 · 2024: 3 · 2023: 3
FWCI
2.01
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Agence Nationale de la Recherche (ANR-11-LABX-0021)
  • Association Nationale de la Recherche et de la Technologie
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
  • Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
Keywords
nutraceuticals, resveratrol, omega-3 fatty acids, age-related macular degeneration, VEGF-A secretion, NF-κB signaling, PI3K/AKT/mTOR pathway, IκB phosphorylation, IκB kinase, bevacizumab, ARPE-19 cells, dietary supplementation
MeSH terms
Bevacizumab, Resveratrol, Humans, Macular Degeneration, Retina, Fatty Acids, Omega-3, Endothelial Growth Factors, NF-kappa B, Dietary Supplements, Phosphatidylinositol 3-Kinases, Vascular Endothelial Growth Factor A, Proto-Oncogene Proteins c-akt, I-kappa B Kinase, TOR Serine-Threonine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Resvega, a Nutraceutical Preparation, Affects NFκB Pathway and Prolongs the Anti-VEGF Effect of Bevacizumab in Undifferentiated ARPE-19 Retina Cells. https://app.cochat.ai/papers/10.3390/ijms231911704
The paper
Sghaier, R., Perus, M., Cornebise, C., Courtaut, F., Scagliarini, A., Olmiere, C., Aires, V., Hermetet, F., & Delmas, D. (2022). Resvega, a Nutraceutical Preparation, Affects NFκB Pathway and Prolongs the Anti-VEGF Effect of Bevacizumab in Undifferentiated ARPE-19 Retina Cells. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms231911704

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.